Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

APRIL 7, 2023

Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Quality and value measurements commonly used outside of the U.S.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

Pharmaceutical Technology

MAY 9, 2023

The 5th Panel of the Federal Court of the 1st Region (Tribunal Regional Federal da 1ª Região, TRF-1) upheld the existing expiry dates of two patents—one for semaglutide itself (2026), and the other for the delivery mechanism for the oral formulation of the drug, Rybelsus (2031).

Marketing 59

Marketing Manufacturing Prospecting Physicians 59

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. To thrive, companies need to plan their launches with different focus.

Doctors 59

Doctors Medicine Marketing Sales 59

Pharmaceutical Technology

JANUARY 10, 2023

The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.

Marketing 52

Marketing Physicians Sales Leads 52

Clarivate

AUGUST 27, 2024

Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. Abbott’s Volt should join the party in early 2026. Still, industry leaders report switching up to 50% of their RF procedures to PFA already. The drop will likely be slower than in cryo, however.

Marketing 52

Marketing Competition FDA Electronics 52

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

PM360

SEPTEMBER 21, 2023

GoodRx is the leading platform 2 with the highest unaided awareness and trust across patients, physicians, and pharmacists 3 that Americans—regardless of insurance status—use across many phases of their healthcare journey. United States Specialty Pharmaceuticals Market & Forecast 2020-2026,” BusinessWire, December 8, 2020.

Prescription 52

Prescription Medical Patients Distribution 52

Pharmaceutical Technology

AUGUST 12, 2022

The Act authorizes the appropriation of $100,000,000 per fiscal year from 2022 to 2026. In the US, most physicians can only spend a day a week, which isn’t efficient, she says. “We The latest action plan was made in accordance with President Biden’s law, ‘Accelerating Access to Critical Therapies for ALS Act’ from December 2021.

FDA 98

FDA Food and Drug Administration Physicians Side effects 98

Clarivate

AUGUST 20, 2024

Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

World of DTC Marketing

JULY 28, 2022

Late last year, the Senate Finance Committee released draft legislation enabling Medicare negotiation for up to 10 drugs in 2025, 15 in 2026 and 2027, and 20 in 2028 and beyond. This would include drugs covered by both Medicare Part B (physician-administered drugs) and Part D (prescription medications). The secretary of the U.S.

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256

Clarivate

OCTOBER 17, 2024

The Inflation Reduction Act instead allows the Centers for Medicare & Medicaid Services to begin negotiating Fair Maximum Prices for a growing list of Part D (outpatient) and Part B (physician-administered) drugs that represent the greatest cost to the federal government. 31, 2024, and providers and payers are pushing for an extension.

Healthcare 52

Healthcare Healthcare Government Insurance 52